Stockreport

CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares  (CASI) 
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: casipharmaceuticals.com/investor-relations